Stocks
Neurocrine Biosciences (NBIX) Debt/EBITDA US GAAP (year values) |
|||||||||
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | LTM ? | CAGR 5 years ? | |||
| Debt/EBITDA | -1.96 | -2.75 | -1.45 | -0.97 | -1.60 | -1.03 | |||
| Changes by years, y/y, % | -25% | +40% | -47% | -33% | +65% | -9.4% | |||
Neurocrine Biosciences. Debt/EBITDA
Neurocrine Biosciences. Debt/EBITDA, changes, %
Neurocrine Biosciences (NBIX) Debt/EBITDA US GAAP (quarter values) |
||||||||
| FY2025Q1 | FY2025Q2 | FY2025Q3 | FY2025Q4 | FY2026Q1 | LTM ? | |||
| Debt/EBITDA | -0.89 | -0.96 | -0.31 | -1.48 | -1.03 | -1.03 | ||
| Changes by years, y/y, % | -25% | -24% | -79% | +53% | +16% | |||
| Changes by quarters, q/q, % | -9% | +9% | -68% | +377% | -30% | |||
